Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents

被引:20
作者
Grant, Christian W. [2 ,3 ]
Moran-Paul, Catherine M. [2 ,3 ]
Duclos, Shane K. [2 ,3 ]
Guberski, Dennis L. [2 ,3 ]
Arreaza-Rubin, Guillermo [1 ]
Spain, Lisa M. [1 ]
机构
[1] NIDDK, NIH, Bethesda, MD USA
[2] Biomed Res Models BRM Inc, Worcester, MA USA
[3] Biomed Res Models BRM Inc, Springfield, MA USA
基金
美国国家卫生研究院;
关键词
MIGRATION INHIBITORY FACTOR; REGULATORY T-CELLS; NOD MICE; AUTOIMMUNE; ANTI-CD3; LISOFYLLINE; THERAPY; REMISSION; BETA; CYCLOSPORINE;
D O I
10.1371/journal.pone.0072989
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We report the results of an independent laboratory's tests of novel agents to prevent or reverse type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse, BioBreeding diabetes prone (BBDP) rat, and multiple autoimmune disease prone (MAD) rat models. Methods were developed to better mimic human clinical trials, including: prescreening, randomization, blinding, and improved glycemic care of the animals. Agents were suggested by the research community in an open call for proposals, and selected for testing by an NIDDK appointed independent review panel. Agents selected for testing to prevent diabetes at later stages of progression in a rodent model were a STAT4 antagonist (DT22669), alpha(1) anti-trypsin (Aralast NP), celastrol (a natural product with anti-inflammatory properties), and a Macrophage Inflammatory Factor inhibitor (ISO-092). Agents tested for reversal of established T1D in rodent models were: alpha(1) anti-trypsin (Aralast NP), tolerogenic peptides (Tregitopes), and a long-acting formulation of GLP-1 (PGC-GLP-1). None of these agents were seen to prevent or reverse type 1 diabetes, while the positive control interventions were effective: anti-CD3 treatment provided disease reversal in the NOD mouse, dexamethasone prevented T1D induction in the MAD rat, and cyclosporin prevented T1D in the BBDP rat. For some tested agents, details of previous formulation, delivery, or dosing, as well as laboratory procedure, availability of reagents and experimental design, could have impacted our ability to confirm prior reports of efficacy in preclinical animal models. In addition, the testing protocols utilized here provided detection of effects in a range commonly used in placebo controlled clinical trials (for example, 50% effect size), and thus may have been underpowered to observe more limited effects. That said, we believe the results compiled here, showing good control and repeatability, confirm the feasibility of screening diverse test agents in an independent laboratory.
引用
收藏
页数:14
相关论文
共 61 条
[1]   Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleuldn-1 Blockade [J].
Ablamunits, Vitaly ;
Henegariu, Octavian ;
Hansen, Jakob Bondo ;
Opare-Addo, Lynn ;
Preston-Hurlburt, Paula ;
Santamaria, Pere ;
Mandrup-Poulsen, Thomas ;
Herold, Kevan C. .
DIABETES, 2012, 61 (01) :145-154
[2]  
[Anonymous], 2011, Guide for the care and use of laboratory animals
[3]  
[Anonymous], 2002, Public Health Service Policy on Humane Care and Use of Laboratory Animals
[4]   Evaluating Preclinical Efficacy [J].
Atkinson, Mark A. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (96)
[5]   Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice [J].
Bojunga, J ;
Kusterer, K ;
Bacher, M ;
Kurek, R ;
Usadel, KH ;
Renneberg, H .
CYTOKINE, 2003, 21 (04) :179-186
[6]   Effective treatment of rat adjuvant-induced arthritis by celastrol [J].
Cascao, R. ;
Vidal, B. ;
Raquel, H. ;
Neves-Costa, A. ;
Figueiredo, N. ;
Gupta, V. ;
Fonseca, J. E. ;
Moita, L. F. .
AUTOIMMUNITY REVIEWS, 2012, 11 (12) :856-862
[7]   Extending Residence Time and Stability of Peptides by Protected Graft Copolymer (PGC) Excipient: GLP-1 Example [J].
Castillo, Gerardo M. ;
Reichstetter, Sandra ;
Bolotin, Elijah M. .
PHARMACEUTICAL RESEARCH, 2012, 29 (01) :306-318
[8]   Essential roles of TGF-β in anti-CD3 antibody therapy:: reversal of diabetes in nonobese diabetic mice independent of Foxp3+ CD4+ regulatory T cells [J].
Chen, Guojiang ;
Han, Gencheng ;
Wang, Jianan ;
Wang, Renxi ;
Xu, Ruonan ;
Shen, Beifen ;
Qian, Jiahua ;
Li, Yan .
JOURNAL OF LEUKOCYTE BIOLOGY, 2008, 83 (02) :280-287
[9]   A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis [J].
Dagia, Nilesh M. ;
Kamath, DivyaV. ;
Bhatt, Popja ;
Gupte, Ravindra D. ;
Dadarkar, Shruta S. ;
Fonseca, Lyle ;
Agarwal, Gautam ;
Chetrayal-Kunwar, Anshu ;
Balachandran, Sarala ;
Srinivasan, Shaila ;
Bose, Julie ;
Pari, Koteppa ;
B-Rao, Chandrika ;
Parkale, Santosh S. ;
Gadekar, Pradip K. ;
Rodge, Atish H. ;
Mandrekar, Noopur ;
Vishwakarma, Ram A. ;
Sharma, Somesh .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 607 (1-3) :201-212
[10]   Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures [J].
Davalli, Alberto M. ;
Perego, Carla ;
Folli, Franco B. ;
Bosi, Emanuele .
ACTA DIABETOLOGICA, 2012, 49 (01) :75-79